H.C. Wainwright has revised its price target for Y-mAbs Therapeutics (YMAB, Financial), reducing it to $11 from a previous target of $12. Despite this adjustment, the firm continues to rate the stock as a Buy. This change comes in the wake of the company's first-quarter financial results.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Y-mAbs Therapeutics Inc (YMAB, Financial) is $15.36 with a high estimate of $26.00 and a low estimate of $3.00. The average target implies an upside of 274.72% from the current price of $4.10. More detailed estimate data can be found on the Y-mAbs Therapeutics Inc (YMAB) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Y-mAbs Therapeutics Inc's (YMAB, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Y-mAbs Therapeutics Inc (YMAB, Financial) in one year is $11.53, suggesting a upside of 181.22% from the current price of $4.1. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Y-mAbs Therapeutics Inc (YMAB) Summary page.
YMAB Key Business Developments
Release Date: May 13, 2025
- DANYELZA Net Product Revenues: $20.9 million in Q1 2025, an 8% increase from Q1 2024.
- Ex-USA DANYELZA Net Product Revenues: $7.5 million, an increase of $6.7 million compared to the prior year period.
- US DANYELZA Net Product Revenues: $13.4 million, down 28% from the prior year period.
- Research and Development Expenses: $11.4 million, a decrease of $1.9 million from Q1 2024.
- Selling and General Administrative Expenses: $13.1 million, an increase of $1.7 million from Q1 2024.
- Net Loss: $5.2 million or negative $0.12 per share, compared to a net loss of $6.6 million or negative $0.15 per share in Q1 2024.
- Cash and Cash Equivalents: $60.3 million at the end of Q1 2025.
- Segment Profit from Operations (DANYELZA): $8.8 million with a 42% segment profit margin.
- Segment Loss from Operations (Radiopharmaceuticals): $6.1 million.
- Q2 2025 Revenue Guidance: Expected to be between $17 million and $19 million.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Y-mAbs Therapeutics Inc (YMAB, Financial) reported DANYELZA net product revenues of $20.9 million for Q1 2025, representing an 8% increase from the same period last year.
- The company successfully completed Part A of the GD2-SADA Phase 1 clinical trial and dosed the first patient in the CD38 SADA Phase 1 clinical trial.
- Y-mAbs Therapeutics Inc (YMAB) has a strong financial position with $60.3 million in cash, providing an anticipated runway into 2027.
- DANYELZA has been added to the NCCN guidelines for the treatment of relapsed or refractory neuroblastoma, which is expected to boost its market presence.
- The company is actively expanding its market reach with new partnerships and investigator-sponsored trials, particularly in high-volume centers and new indications.
Negative Points
- US DANYELZA net product revenues decreased by 28% compared to the prior year period, due to competitive pressures and changes in ordering patterns.
- The company did not record any licensing revenue for Q1 2025, compared to $0.5 million in the same period last year.
- Research and development expenses decreased by $1.9 million, indicating potential scaling back in certain areas.
- Selling and general administrative expenses increased by $1.7 million, partly due to personnel costs and business realignment charges.
- The company reported a net loss of $5.2 million for Q1 2025, although this was an improvement from the previous year's loss.
